|
|
Volumn 8, Issue 8, 2009, Pages 599-600
|
|
Public-private partnership tackles TB challenges in parallel
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL;
2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE;
6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE;
ETHAMBUTOL;
ISONIAZID;
PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;
PYRAZINAMIDE;
RIFAMPICIN;
ANTIVIRAL SUSCEPTIBILITY;
ARTICLE;
CELL SCREENING;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
DRUG DETERMINATION;
DRUG EFFICACY;
DRUG POTENCY;
DRUG TARGETING;
GENE MUTATION;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HUMAN;
MULTIDRUG RESISTANT TUBERCULOSIS;
MYCOBACTERIUM TUBERCULOSIS;
NONHUMAN;
PRIORITY JOURNAL;
PROGRAM DEVELOPMENT;
TREATMENT DURATION;
TUBERCULOSIS;
ANTITUBERCULAR AGENTS;
COOPERATIVE BEHAVIOR;
DRUG DESIGN;
DRUG INDUSTRY;
HUMANS;
MYCOBACTERIUM TUBERCULOSIS;
ORGANIZATIONS, NONPROFIT;
QUINOLINES;
TUBERCULOSIS;
TUBERCULOSIS, MULTIDRUG-RESISTANT;
|
|
EID: 68249102793
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2955 Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|